Theories behind Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer and update on current management
Bladder cancer encapsulates a wide spectrum of disease severities, with non-muscle invasive bladder cancer (NMIBC) representing an entirely different entity from muscle-invasive disease. Bacillus Calmette-Guérin (BCG) is one of the most successful intravesical treatment methods for patients diagnose...
Main Authors: | Hanna Maroof, Louise Paramore, Ahmed Ali |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Cancer Pathogenesis and Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2949713223000939 |
Similar Items
-
Systemic bacillus Calmette-Guérin (BCG) infection and accompanying warm autoimmune haemolytic anaemia following intravesical BCG immunotherapy
by: Alper Tuna Güven, et al.
Published: (2023-08-01) -
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study
by: Joongwon Choi, et al.
Published: (2024-05-01) -
Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
by: Dayoung Ko, et al.
Published: (2022-04-01) -
A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022
by: Masashi Nishimura, et al.
Published: (2023-01-01) -
The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
by: Jong Ho Park, et al.
Published: (2024-11-01)